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Histone acetylation is a diagnostic feature of tran-
scriptionally active genes. The proper recruitment and
function of histone acetyltransferases (HATs) and
deacetylases (HDACs) are key regulatory steps for gene
expression and cell cycle. Functional defects of either of
these enzymes may lead to several diseases, including
cancer. HATs and HDACs thus are potential therapeutic
targets. Here we report that garcinol, a polyisopreny-
lated benzophenone derivative from Garcinia indica
fruit rind, is a potent inhibitor of histone acetyltrans-
ferases p300 (IC50 7 M) and PCAF (IC50 5 M) both in
vitro and in vivo. The kinetic analysis shows that it is a
mixed type of inhibitor with an increased affinity for
PCAF compared with p300. HAT activity-dependent
chromatin transcription was strongly inhibited by gar-
cinol, whereas transcription from DNA template was not
affected. Furthermore, it was found to be a potent in-
ducer of apoptosis, and it alters (predominantly down-
regulates) the global gene expression in HeLa cells.
The acetylation and deacetylation of histones play a key
role in the regulation of gene expression in eukaryotic cells
(1). The acetylation status of histones alters chromatin struc-
ture and thereby modulates gene expression. Two classes of
enzymes can effect the acetylation of histones, histone acetyl-
transferases (HATs),1 and histone deacetylases (HDACs) (1,
2). Interestingly, these enzymes can also acetylate or
deacetylate several non-histone substrates with functional
consequences (1, 3). Altered HAT and HDAC activities can
lead to several diseases, ranging from cancer to neurodegen-
erative diseases (4–7).
Several families of HATs have recently been identified,
which includes the GNAT family (GCN5-related N-acetyltrans-
ferase), the MYST group, SAS2, TIP60, and p300/CBP families
(1, 3). The p300/CBP family of HAT is represented by two of the
most widely studied HATs, p300 and CBP. These proteins
share considerable sequence and functional homology. Several
lines of evidence indicate that p300/CBP are involved in cell
cycle progression and cellular differentiation (8–11). Mechanis-
tically, these proteins function as transcriptional coactivators
through their direct interaction with a diverse group of tran-
scription factors and the RNA polymerase II transcription ma-
chinery. The coactivation function is partially facilitated by
their intrinsic HAT activity (12, 13). Mutations in the HAT
active site abolish transactivating function (1). The p300/CBP-
associated factor, PCAF is one of the important HATs of the
GNAT family. The C-terminal-half of PCAF has a highly sig-
nificant sequence similarity to yeast GCN5 (14). In humans
there are two GCN5 splice variants, hGCN5 and hGCN5-L
(long form) synthesized from the same gene. The hGCN5-L is
similar in length to PCAF and shares 75% amino acid sequence
identity with PCAF. It also interacts with p300/CBP. The
hGCN5-L is thus termed as PCAF-B (15). PCAF-B is an essen-
tial gene expressed ubiquitously early in development, whereas
PCAF is expressed later in embryonic development and is not
essential (16). In vivo PCAF exists in a large multiprotein
complex, containing more than 20 different polypeptides (17).
Unlike p300/CBP (which acetylates all the four core histones,
predominantly H3 and H4) PCAF acetylates predominantly
histone H3. For nucleosomal histone substrates, this specificity
is quite exclusive. The acetylase domain of PCAF is required for
MyoD-dependent coactivation and differentiation. Presumably
the acetyltransferase activity of PCAF and PCAF-B is also
involved in DNA repair (15). Both p300/CBP and PCAF also
target non-histone protein substrates, which include, human
transcriptional coactivators, PC4 (18), HMGB-1 (19), HMG17,
HMGI/Y; transcription factors E2F, p53, GATA1 (3), and HIV
Tat protein (20, 21). The acetylation of these factors alters their
DNA/nucleosome binding and/or protein-protein interactions
and consequently influences their effect in regulating gene
transcription.
It is thus evident that proper balance of acetylation and
deacetylation is important for normal cell proliferation, growth,
and differentiation. The dysfunction of these machineries leads
to different diseases. Several lines of evidence indicate that
HAT activity is associated with tumor suppression, and the loss
or misregulation of this activity may lead to cancer. For exam-
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ple, viral oncogene proteins E1A target p300/CBP, disrupting
its interaction with PCAF (14). E1A interaction with p300/CBP
is essential for cellular transformation. Chromosomal translo-
cations associated with certain leukemias indicate that gain-
of-function mutations in CBP is also oncogenic (22). Mutations
in HATs cause several other disorders other than cancer. Mu-
tations in CBP result(s) in the Rubinstein-Taybi syndrome
(RTS) (23). It was found that a single mutation at the PHD
domain of CBP causes this syndrome. Interestingly, this mu-
tation (G to C at 4951) in CBP also abolishes its HAT activity
(23, 24). Degradation of CBP/p300 was found to be associated
with certain neurodegenerative diseases (7). Proper HAT func-
tion is also essential for the replication of HIV. It was elegantly
shown that treatment with HDAC inhibitors inhibits the la-
tency of HIV, presumably by inducing acetylation of Tat pro-
tein and the nucleosomes on the LTR (25, 26). These examples
clearly indicate that histone acetyltransferases and deacetyl-
ases should be one of the potential targets for therapy. During
the last decade, a number of HDAC inhibitors have been iden-
tified that induce apoptosis in cultured tumor cells (4). These
inhibitors were also found to be potent anticancer agents in
vivo. Furthermore, some of these inhibitors (e.g. SAHA) are
already in human trial as antineoplastic drug (27). Although
substantial progress has been made in the study of HDAC
inhibitors, very little is known about HAT inhibitors. Initially,
before the discovery of HATs, polyamine-CoA conjugates were
found to inhibit the acetyltransferase activity of cell extracts
(28). Availability of recombinant HATs (p300 and PCAF) made
it possible to synthesize more targeted specific inhibitors, Lys-
CoA for p300 and H3-CoA-20 for PCAF (29). However, these
inhibitors could not permeate the cells and were found to be
pharmacogenically poor (30). Recently, we have discovered a
natural inhibitor anacardic acid from cashew nut shell liquid
that potently inhibits both p300 and PCAF (31). Based on
anacardic acid we have synthesized a small molecule activator
of p300, CTPB. Interestingly, CTPB is specific for p300. Both
anacardic acid and CTPB may serve as potential lead com-
pounds for designing different drugs.
Here we report that a polyisoprenylated benzophenone, gar-
cinol, isolated from Garcinia indica (an edible fruit) is a potent
inhibitor of histone acetyltransferases p300 and PCAF. It
also inhibits histone acetylation in vivo but has no effect on
deacetylation of histones. Interestingly, though garcinol re-
pressed the p300 HAT-dependent chromatin transcription, it
had no effect on naked DNA transcription. Furthermore mi-
croarray analysis of gene expression in garcinol-treated HeLa
cells showed that it represses transcription globally with an
appreciable chromosome bias.
EXPERIMENTAL PROCEDURES
Purification of Human Core Histones and Recombinant Proteins—
Human core histones were purified from HeLa nuclear pellet as de-
scribed previously (32). The FLAG epitope-tagged human histone
deacetylase 1 (HDAC1), and PCAF were purified from the recombinant
baculovirus-infected insect cell line Sf21 by immunoaffinity purification
using M2 agarose (Sigma) (32). Full-length p300 was also purified from
the recombinant baculovirus-infected Sf21 cells as a His6-tagged pro-
tein through the nickel-nitrilotriacetic acid affinity column (Qiagen) as
described previously (12). The His6-tagged nucleosome assembly pro-
tein 1 (NAP1) used for the in vitro chromatin assembly was purified
from Escherichia coli cells as reported previously (32). The FLAG-
tagged chimeric activator Gal4-VP16 was expressed in E. coli and
purified by immunoaffinity purification with M2 agarose (Sigma) (12).
His6-tagged D-topoisomerase 1 (catalytic domain) was expressed in
E. coli and purified as described earlier (33).
Purification and Structural Analysis of Garcinol—Garcinol was pre-
pared from Garcinia indica fruit rind (46). In brief, G. indica dried fruit
(Kokum) rind was extracted with ethanol, and the extract was fraction-
ated by ODS (octadecyl silica) column chromatography eluted stepwise
with 60–80% aqueous ethanol. The fractions containing garcinol were
concentrated and dried in vacuum. The residue was dissolved in hex-
ane, and the solution was cooled at 5 °C for 2 days. Yellow amorphous
precipitate was collected from the solution and washed with cold hex-
ane and recrystallized at room temperature. Pale yellow needle crystals
were obtained from the solvent, which were identified as garcinol from
the following spectral data: mp 126 °C; Optical rotation at 30–135
(CHCl3); UV in EtOH (log ) 367 (3.84) and 250 (4.05) nm; IR 3200–
3500, 1730, 1640 cm1; 1H NMR (CDCl3)  6.95 (1H, dd, J  9.0 and 2.0
Hz), 6.91 (1H, d, J  2.0 Hz), 6.60 (1H, d, J  9.0 Hz), 4.96, 5.06, 5.10
(1H each, t, J  5.0 Hz), 4.40 (d, J  15.0 Hz), 2.80–1.46 (m, 12H,
methylene and methyne), 1.78, 1.74, 1.69, 1.62, 1.59, 1.56, 1.21, 1.05
(3H each, s); EI-MS m/z 602 [M], 533, 465, 341.
HAT Assay—The protocol used for the HAT assays is described
elsewhere (32). Indicated amounts of proteins (see figure legends) were
incubated in HAT assay buffer containing 50 mM Tris-HCl, pH 8.0, 10%
(v/v) glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride,
0.1 mM EDTA pH 8.0, 10 mM sodium butyrate at 30 °C for 10 min in the
presence and absence of garcinol followed by addition of 1 l of 4.7
Ci/mmol [3H]acetyl-CoA and were further incubated for another 10 min.
The final reaction volume was 30 l. The reaction mixture was then
blotted onto P-81 (Whatman) filter paper and radioactive counts were
recorded on a Wallace 1409 liquid scintillation counter. To visualize
radiolabeled acetylated histones, the reaction products were resolved on
15% SDS-polyacrylamide gel and subjected to fluorography followed by
autoradiography as described earlier (32). For the kinetic analysis of
garcinol-mediated inhibition of HATs, a filter binding assay was per-
formed as described in figure legends (Fig. 3).
HDAC Assay—The deacetylation assay was performed as described
previously (31), Briefly 2.4 g of core histones were incubated in HAT
buffer without NaBu, with 20 ng of p300 and 1 l of 4.7 Ci/mmol
[3H]acetyl-CoA for 30 min at 30 °C. The activity of p300 was inhibited
by incubating the reaction mixture with 10 nM p300-specific inhibitor
lysyl-CoA (29) for 15 min at 30 °C, after which 50 ng of HDAC1 was
added in the presence or absence of garcinol and incubated further for
45 min at 30 °C. The samples were analyzed as described above.
Analysis of in Vivo Acetylated Histones by Acid/Urea/Triton (AUT)
Polyacrylamide Gel Electrophoresis—HeLa cells (3  106 cells per
90-mm dish) were seeded overnight, and histones were extracted from
the cells after 24 h of compound treatment as described elsewhere (34).
Briefly, cells were harvested, washed in ice-cold buffer A (150 mM KCl,
20 mM HEPES, pH 7.9, 0.1 mM EDTA, and 2.5 mM MgCl2) and lysed in
buffer A containing 250 mM sucrose and 1% (v/v) Triton X-100. Nuclei
were recovered by centrifugation, washed, and proteins were extracted
for 1 h using 0.25 M HCl. Chromosomal proteins were precipitated with
25% (w/v) trichloroacetic acid and sequentially washed with ice-cold
acidified acetone (20 l of 12 N HCl in 100 ml of acetone), and acetone,
air-dried, and dissolved in the sample buffer (5.8 M urea, 0.9 M glacial
acetic acid, 16% glycerol, and 4.8% 2-mercaptoethanol). The protein was
quantified using a protein assay reagent (Bio-Rad). The histones were
resolved on AUT gel as described elsewhere (35, 36). Briefly, 8 cm of the
separating gel (1 M acetic acid, 8 M urea, 0.5% Triton X-100, 45 mM NH3,
18% acrylamide mix, and 0.5% TEMED) was overlaid with 2 cm of an
upper gel (1 M acetic acid, 8 M urea, 0.5% Triton X-100, 45 mM NH3, 3.3%
acrylamide, 0.16% bisacrylamide, and 0.5% TEMED) and polymeriza-
tion was aided with 0.0003% riboflavin. The gel was pre-electrophore-
sed for 3–4 h at 130 V in running buffer (1 M acetic acid) until the
current no longer dropped. Fresh running buffer was added prior to
loading the samples (0.2% methyl green was added as the tracking dye),
and the gel was run overnight at 130 V and subsequently stained with
Coomassie Brilliant Blue.
In Vitro Chromatin Assembly—Chromatin template for in vitro tran-
scription experiments was assembled and characterized as described
earlier (12).
In Vitro Transcription Assay—Transcription assays were essentially
carried out as described previously (12) with some modifications. The
scheme of transcription has been depicted in Fig. 5A. Briefly, the
reconstituted chromatin template (containing 30 ng of DNA) or an
equimolar amount of histone-free DNA was incubated with 50 ng of
activator (Gal4-VP16) in a buffer containing 4 mM HEPES (pH 7.8), 20
mM KCl, 2 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 10
mM sodium butyrate, 0.1 mg/ml bovine serum albumin, 2% glycerol.
p300 was preincubated with indicated amounts of garcinol at 20 °C for
20 min following which it was added to the transcription reaction and
incubated for 30 min at 30 °C. After acetylation, HeLa nuclear extract
(5 l, which contains 8 mg/ml protein) was added to initiate the preini-
tiation complex formation. Transcription reaction was started by the
addition of NTP mix and -[32P]UTP after the preinitiation complex
formation. The incubation was continued for 40 min at 30 °C. A sepa-
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rate reaction was setup with 25 ng of supercoiled ML200 DNA, and
the transcription assay was carried out as described above, without the
addition of the activator (Gal4-VP16). 2 l of this reaction was added to
each of the transcription reactions to serve as a loading control. The
transcription reactions were terminated by the addition of 250 l of stop
buffer (20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 100 mM NaCl, 1% SDS,
and 0.025 ng/l tRNA). Transcripts were analyzed by 5% Urea-PAGE
and visualized by autoradiography. Quantification of transcription was
done by phosphorimager (Fuji) analysis.
Apoptosis Assay—Garcinol-induced apoptosis was monitored by the
extent of chromatin fragmentation. DNA was extracted from the un-
treated and garcinol-treated HeLa cells. The cells (3  106 per 90-mm
dish) were seeded and treated with the compound for 24 h. Harvested
cells were washed with PBS and then lysed with lysis buffer containing
0.5% Triton X-100, 20 mM Tris, and 15 mM EDTA at room temperature
for 15 min. The lysate was treated with RNase (0.1 mg/ml) and protein-
ase K (2 mg/ml) for 1 h, extracted with phenol/chloroform/isoamyl
alcohol (25:24:1), and DNA was precipitated by incubating the upper
aqueous phase with 0.1 volumes of 3 M sodium acetate (pH 5.2) and 1
volume of isopropyl alcohol overnight at 20 °C. The pellet obtained on
centrifugation was washed with 70% ethanol and dissolved after air-
drying in 50 l of TE buffer. The extracted DNA was analyzed on a 1.8%
agarose gel and visualized by ethidium bromide staining. Nuclei frag-
mentation was also visualized by Hoechst staining of apoptotic nuclei.
The apoptotic cells were collected by centrifugation, washed with PBS
and fixed in 4% paraformaldehyde for 20 min at room temperature.
Subsequently the cells were washed and resuspended in 20 l of PBS
before depositing it on polylysine-coated coverslips. The cells were left
to adhere on cover slips for 30 min at room temperature after which the
cover slips were washed twice with PBS. The adhered cells were then
incubated with 0.1% Triton X-100 for 5 min at room temperature and
rinsed with PBS for three times. The coverslips were treated with
Hoechst 33258 for 30 min at 37 °C, rinsed with PBS, and mounted on
slides with glycerol-PBS. Stained nuclei were analyzed by using Axios-
kop-2- plus upright microscope with epi-fluorescence equipment (Carl
Zeiss), and the image was captured by Axiocam MRC camera and
analyzed by AxioVision 3.1 software.
Microarray Analysis—The microarrays used in this study were pro-
cured from the Microarray center, University Health Network, Toronto,
Ontario. Each array carries 19,200 spots from the human genome,
arranged in 48 individual arrays of 400 spots each. Each of the 48 grids
contains 3 Arabidopsis spots that serve as local controls. The total RNA
was isolated from control and treated cells using RNaeasy kit (Sigma,
74103). The micromax indirect labeling kit (PerkinElmer Life Sciences,
MPS521) was used to synthesize the labeled cDNA from 4 g of total
RNA and further process the hybridized cDNA on the array by the
FIG. 1. A, chemical structure of garcinol. B, purified proteins used in different experiments. Highly purified core histones (3 g) from HeLa
nuclear pellet were analyzed on 15% SDS-PAGE. Lane 1, visualized by Coomassie Blue staining; lane 2, 300 ng of baculovirus-expressed FLAG
epitope-tagged, full-length human HDAC1 analyzed on 10% SDS-PAGE; lane 3, 150 ng of full-length, His6-tagged p300; lane 4, 200 ng of FLAG
epitope-tagged full-length PCAF; lane 5, 300 ng of His6-tagged mouse NAP1 each analyzed on 8% SDS-PAGE; lane 6, 300 ng of E. coli expressed
His6-tagged Drosophila toposiomerase 1 (catalytic domain) were analyzed on 8% SDS-PAGE stained with Coomassie Blue.
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tyramide signal amplification method (37). All steps were carried out
according to manufacturer’s recommendations (www.nen.com/pdf/
penen264-mmaxaminated_card.pdf). The array slides were scanned im-
mediately using a GenePix Presonal 4100A Axon Scanner. The images
were analyzed using the GenePix software and the Genowizard soft-
ware (Genotypic Technology, Bangalore) was used for grid wise normal-
ization of the array. Six arrays were used with two biological repeats of
the treatment of cells and at least two dye swap experiments were
included in the final analysis. The genes that were picked up as differ-
entially regulated had a log mean of at least 1.27489 with S.D. less than
20% of the expression change in the case of up-regulated genes and a log
mean of almost 1.75726 with S.D. less than 37% of the expression
change in case of the down-regulated genes. Guidelines set by MIAME
were followed, and the raw microarray data will be deposited in the
GEO data base (www.ncbi.nlm.nih.gov/geo/).
RESULTS AND DISCUSSION
Dysfunction of histone acetyltransferases may lead to sev-
eral diseases, predominantly cancer. Plant extracts or com-
pounds known to have anticancer or cancer chemopreventive
activities could be a source of small molecule modulators of
HATs. By employing a highly purified recombinant HAT assay
system, we have initiated a systematic effort to discover these
molecules. Interestingly, a polyisoprenylated benzophenone
from G. indica fruit rind has been found to be a potent inhibitor
of histone acetyltransferases. Structural analysis identified it
as the antioxidant and cancer chemopreventive agent garcinol
(Fig. 1A). The HAT inhibitory activity was assayed using bacu-
lovirus-expressed recombinant histone acetyltransferase p300
and PCAF (Fig. 1B, lanes 3 and 4) and highly purified HeLa
core histones as substrate (Fig. 1B, lane 1). Garcinol was found
to be a highly efficient inhibitor of PCAF acetyltransferase
activity with an IC50 of 5 M. Under similar conditions the
IC50 of the inhibitor for p300 acetyltransferase activity was 7
M (Fig. 2A and data not shown). These results suggest that
although garcinol inhibits the HAT activity of both p300 and
PCAF, it is relatively more potent as well as a faster inhibitor
of PCAF compared with p300. In order to further confirm these
results we analyzed HAT assay products on SDS-PAGE fol-
lowed by fluorography. In agreement with the results of the
p300 filter binding assay, it was found that the HAT activity of
PCAF was almost completely inhibited by 10 M garcinol com-
pared with the Me2SO control, (Fig. 2B, lane 3 versus 6)
whereas even at 20 M concentration, 5–10% of 3H-labeled
histone H3 could be detected (Fig. 2B, lane 3 versus 7). Inter-
estingly it was found that acetylation of histone H4 by p300
was more sensitive to inhibition by garcinol compared with
FIG. 2. Garcinol is a potent inhibitor of HATs. HAT assays were performed either with p300 or PCAF in the presence or absence of garcinol
using highly purified HeLa core histones (800 ng) and processed for filter binding (A) or fluorography (B). For fluorography, reaction mixtures were
analyzed on 15% SDS-polyacrylamide gel and exposed to x-ray film for 72 h. Lane 1, core histones without any HAT; lane 2, histones with HAT;
lane 3, histones with HAT and in the presence of Me2SO as solvent control; lanes 4–7, histones with HAT and in the presence of 0.5, 1, 10, 20 M
concentrations of garcinol, respectively. C, effect of garcinol on cellular histone acetylation. HeLa cells were treated as indicated, for 24 h. Histones
were acid-extracted and analyzed over 18% acid/urea/Triton-PAGE. The protein bands were visualized by Coomassie Brilliant Blue staining.
Histones extracted from untreated cells (lane 1), Me2SO- (DMSO, solvent control) treated cells (lane 2), garcinol- (100 M) treated cells (lane 3),
trichostatin- (2 M) and sodium butyrate- (10 mM) treated cells (lane 4), and trichostatin- A (2 M), sodium butyrate- (10 mM), and garcinol- (100
M) treated cells (lane 5) are shown. Asterisk (*) indicates hyperacetylation of histones H4 and H2B in response to HDAC inhibition by TSA and
sodium butyrate. Arrow indicates inhibition of TSA-induced hyperacetylation of H4 and H2B by garcinol.
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that of H3 (Fig. 2B, top panel, lanes 4–7). The p300-mediated
acetylation of histone H4 was completely inhibited at a 1 M
concentration of garcinol, while 20 M could not abolish the
acetylation of H3 (Fig. 2B, top panel, lane 5 versus lane 7). After
establishing garcinol as a strong inhibitor of HATs in vitro, we
further investigated whether it could also affect the acetylation
of histones in vivo. For this purpose HeLa cells were grown in
monolayer (see “Experimental Procedures”) and were treated
with either Me2SO (the solvent for garcinol) or different con-
centrations of garcinol. Histones were extracted from the cell
pellet and analyzed on an 18% acid/urea/Triton polyacrylamide
gel electrophoresis. As seen from the profile of different his-
tones (Fig. 2C), incubation with the compound alone did not
alter the acetylation status of the cellular histones signifi-
cantly. In agreement with previous reports (38) the bulk his-
tones from HeLa cells are found to be largely unacetylated (Fig.
2C, lanes 1–3). Because the global acetylation of histones for
asynchronous cells does not change significantly, it was not
possible to determine the effect of HAT inhibitor on histone
acetylation. In order to stimulate histone acetylation, cells
were treated with the deacetylase inhibitors TSA and sodium
butyrate. As expected deacetylase inhibitors enhance the acety-
lation of histone H4 as well as H2B dramatically (Fig. 2C, lane
4). The treatment of the cells with garcinol along with TSA and
sodium butyrate significantly inhibits the enhanced acetyla-
tion of H4 as well as H2B (Fig. 2C, compare lane 4 versus 5 as
indicated by an arrow). Taken together, these results establish
that garcinol is a potent inhibitor of histone acetyltransferases
in vitro and in vivo.
In order to understand the nature of inhibition as well as
the mechanism of inhibition brought about by garcinol we
analyzed the kinetics of inhibition for both p300 (Fig. 3A) and
PCAF (Fig. 3B). The rate of the acetylation reaction at dif-
ferent concentrations of the inhibitor (and in its absence) was
recorded with increasing concentrations of [3H]acetyl-CoA
and a constant amount of core histones as well as with
increasing concentrations of core histones with constant
amounts of [3H]acetyl-CoA. The double reciprocal plot for
each inhibitor concentration and in its absence was plotted as
shown in Fig. 3. The kinetic results show that the inhibition
patterns for p300 and PCAF are similar. When the concen-
tration of acetyl-CoA was changed keeping the histone con-
centration constant, Km increases, whereas Vmax and kcat of
the reaction decrease (Fig. 3, A and B, left panel and Table I).
On the other hand, increasing concentrations of histones with
constant amounts of [3H]acetyl-CoA increase Km but Vmax
and kcat remain the same (Fig. 3, A and B, right panel and
Table I), which indicates that in this context garcinol com-
petes with histones for binding to the active site of the en-
zyme and thus acts as a competitive inhibitor.
The reaction mechanism for p300 and PCAF to acetylate the
lysine residues is contrastingly different. The GNAT family
members, PCAF and serotonin N-acetyltransferase, and GCN5
employ ternary complex mechanisms that involve the ordered
binding and release of substrates and products (39). On the
other hand, the p300/CBP family follows the double displace-
ment (ping-pong) mechanisms (40). The dead end analogue of
acetyl-CoA, desulfo-CoA was shown to be a linear competitive
inhibitor versus acetyl-CoA but it behaves as a linear uncom-
petitive inhibitor versus peptide substrate. Garcinol-mediated
inhibition kinetics (for both p300 and PCAF) shows that with
changing concentrations of acetyl-CoA it behaves like an un-
competitive type of inhibitor whereas for core histones, as a
competitive inhibitor. These differences in the inhibition pat-
FIG. 3. Inhibition kinetics of garcinol for p300 (A) and PCAF (B). A(1), and B(1), Lineweaver-Burk plot showing the effect of garcinol on
p300- and PCAF-mediated acetylation of highly purified HeLa core histones, respectively. HAT assays were carried out with a fixed concentration,
of [3H]acetyl-CoA (354 nM) and increasing concentrations of histones (0.033–0.165 M) in the presence or absence of (5 and 7 M) of garcinol. A(2),
and B(2), depicting the same Lineweaver-Burk plot representation of garcinol effect on p300 and PCAF HAT activity at a fixed concentration of
histone (8 pmol) and increasing concentrations of [3H]acetyl-CoA in the presence (5 and 7 M) or absence of garcinol. The results were plotted using
GraphPad Prism software.
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tern indicate the mechanistic uniqueness of garcinol.
In order to ensure enzyme specificity as well as substrate
specificity we went on to check the effect of garcinol on the
HDAC1 enzyme. The HDAC assay protocol was followed as
described previously (31). Deacetylation of core histones in the
presence or absence of the compound, garcinol (10 or 20 M)
shows no difference whatsoever (Fig. 4, lanes 7 and 8 versus
lane 3). Addition of the solvent of garcinol, Me2SO, has no effect
on the deacetylation of core histones by the recombinant
HDAC1 (Fig. 4, lane 5). Therefore we can presume that garcinol
is specific to HAT activity. In order to verify this HAT specific-
ity we used the HAT-dependent in vitro chromatin transcrip-
tion assay system as described previously (12). The chromatin
template was assembled on pG5-ML-array (12) by employing
the NAP1 assembly system. The assembled chromatin was
characterized by DNA supercoiling and partial micrococcal
(MNase) digestion assay (Fig. 5, B and C). As depicted in the
figure, a substantial amount of relaxed DNA was found to be
supercoiled upon deposition of nucleosome (Fig. 5B, lane 2
versus lane 3). Because the supercoiling assay does not assure
the proper spacing of the histone octamer, partial micrococcal
digestion was performed wherein we found 4 to 5 well resolved
regularly spaced nucleosomes (Fig. 5C). The results of these
assays suggest that the assembled chromatin is appropriate for
in vitro transcription experiments. The transcription assay
followed the protocol depicted in Fig. 5A. To establish the
HAT-specific nature of garcinol, we tested its effect on tran-
scription from DNA, which is not HAT-dependent (Fig. 5D).
The chimeric transcriptional activator, Gal4-VP16 activates
transcription around 10-fold compared with basal transcription
without any activator (Fig. 5D, lane 2 versus 1). Addition of
solvent (Me2SO) or 20 M and 50 M garcinol shows no effect on
the activator-dependent transcription (Fig. 5D, lanes 3–5). The
activator-independent transcription from the ML200 promoter
was used as a loading control. As reported previously, tran-
scription from the chromatin template shows complete depend-
ence on acetylation (absolute requirement of acetyl-CoA), as
depicted in Fig. 5E (lane 3 versus 4). Addition of Me2SO, mar-
ginally represses the transcription (Fig. 5E, lane 4 versus 5).
Interestingly, increasing concentrations of garcinol (especially
50 M) dramatically represses HAT-dependent chromatin tran-
scription (Fig. 5E, lane 5 versus 7). These data show that
garcinol specifically inhibits HAT activity-dependent chroma-
tin transcription but not transcription from the DNA template.
We have shown that garcinol is a potent inhibitor of HATs
both in vitro and in vivo. Furthermore, it also inhibits the
HAT-dependent transcription from chromatin template. In or-
der to further understand its effect in vivo, we treated the HeLa
cells with increasing concentrations of garcinol and performed
the apoptosis assay. The effect of garcinol on chromatin frag-
mentation was investigated for this purpose. HeLa cells treated
with hydrogen peroxide to induce the apoptosis were taken as
FIG. 4. Garcinol does not affect the histone deacetylase activity of histone deacetylase 1. 2.4 g of 3H-labeled highly purified HeLa core
histones (by p300) were subjected to deacetylation with 60 ng of recombinant HDAC 1 in the presence (10 and 20 M) or absence of garcinol. Lane
1, unlabelled histones; lane 2, acetylated histones; lane 3, acetylated histones treated with HDAC1; lane 4, acetylated histones treated with Me2SO
(DMSO); lane 5, deacetylation of histones in the presence of Me2SO (DMSO); lane 6, acetylated histones with garcinol (10 M); lanes 7 and 8,
deacetylation of acetylated histones by HDAC1 in the presence of 10 M and 20 M garcinol, respectively.
TABLE I
Inhibition kinetic parameters
Substrate Km Vmax kcat/s Substrate Km Vmax kcat/s
M M
p300
Histones 0.03 6250 0.69 Acetyl-CoA 0.25 7468 0.82
5 M garcinol 0.095 6250 0.69 5 M garcinol 0.42 6501 0.72
7 M garcinol 0.151 6250 0.69 7 M garcinol 0.53 5288 0.58
PCAF
Histones 0.028 5175 0.57 Acetyl-CoA 0.177 4889 0.53
5 M garcinol 0.099 5175 0.57 5 M garcinol 0.227 3487 0.38
7 M garcinol 0.169 5175 0.57 7 M garcinol 0.282 2751 0.30
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FIG. 5. Garcinol inhibits p300 HAT activity-dependent transcriptional activation from the chromatin template. A, schematic
representation of the in vitro transcription protocol. B, DNA supercoiling assay for assembled chromatin. Lane 1, supercoiled DNA used for
assembly; lane 2, relaxed DNA (after dTopoI treatment of the DNA of lane 1); lane 3, chromatinized DNA isolated by deproteinization. C, MNase
digestion pattern of assembled chromatin. The chromatin was treated with increasing concentrations of MNase at room temperature. After
deproteinization, the resulting DNA was resolved on a 1.5% agarose gel and stained with ethidium bromide. In vitro transcription from naked DNA
(D) and chromatin template (E). 30 ng of DNA and freshly assembled chromatin template (equivalent to 30 ng of DNA) were subjected to the
protocol in A with or without garcinol, 50 ng of Gal4-VP16, 25 ng of baculovirus-expressed highly purified His6-tagged p300 (full-length) and 1.5
M acetyl-CoA. The in vitro transcription reaction mixtures were analyzed on 5% urea-acrylamide gel and further processed by autoradiography.
D, lane 1, without activator (basal transcription); lane 2, with activator (Gal4-VP16); lane 3, with activator and Me2SO; lanes 4 and 5, with activator
and 20 and 50 M garcinol. E, lane 1, without activator; lane 2, with activator; lane 3, with activator and p300, lane 4, with activator, p300 and
acetyl-CoA, lane 5, reaction of lane 4 in the presence of Me2SO, lanes 6 and 7, reaction of lane 4 in the presence of 20 and 50 M garcinol.
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a positive control to test garcinol-mediated apoptosis. Frag-
mented chromatin was analyzed on a 1.8% agarose gel (Fig.
6A). The cells treated with buffer or solvent (Me2SO) did not
show any obvious differences (Fig. 6A, lanes 1 versus 3), but
treatment with hydrogen peroxide yielded huge amounts of
faster moving species of DNA fragments (Fig. 6A, lane 2).
Similar to hydrogen peroxide treatment, increasing concentra-
tions of garcinol (30, 70, and 100 M) also induce apoptosis and
generate smaller DNA fragments (Fig. 6A, compare lane 2 with
4 and 6). To visualize the chromatin fragmentation in situ,
compound-treated nuclei were stained with Hoechst (which
stains the DNA). In agreement with the DNA fragmentation
data Hoechst staining of the nuclei also shows that treatment
with 50 and 100 M garcinol induces the fragmentation of
nuclei, as indicated by arrows (Fig. 6B, panels c and d). Taken
together these data show that the histone acetyltransferase
inhibitor garcinol stimulates the apoptosis in HeLa cells.
The histone acetyltransferase specificity, induction of apo-
ptosis, and more significantly the ability of garcinol to inhibit
the histone acetylation in vivo prompted us to investigate its
effect on global gene regulation. HeLa cells were treated with
100 M garcinol for 24 h and subjected to microarray analysis
to investigate its effect on global gene regulation. Genome
wide analysis of gene expression using microarrays indicates
FIG. 7. The percent of differentially expressed genes per chromosome are represented as a bar graph. The pie chart represents
the known and unknown fraction of differentially expressed genes.
FIG. 6. Garcinol induces apoptosis in HeLa cells. HeLa cells grown in monolayer were treated with garcinol and subjected to apoptosis
assay. A, agarose gel electrophoresis of the DNA extracted from the compound-treated cells. Fragmentation of nucleosomal DNA was visualized
by ethidium bromide staining. Lane 1, untreated cells; lane 2, hydrogen peroxide-treated; lane 3, Me2SO-treated; and lanes 4–6, cells treated with
30, 70, and 100 M garcinol respectively. B, Hoechst staining of HeLa cells treated with Me2SO (DMSO) (panel b) and 50 and 100 M garcinol
(panels c and d). Panel a shows untreated control. Arrows indicate apoptotic nuclear fragmentation.
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TABLE II
Genes differentially expressed with treatment of the HAT inhibitor, garcinol
Category ACCIDa Genes down-regulated
Apoptosis R70836 BCL2-like 2
W25164 BCL-6 interacting corepressor
R12025 Bifunctional apoptosis regulator
T78664 Death-associated protein kinase 1
R26621 Fas apoptotic inhibitory molecule 2
R32216 p53-induced protein PIGPC1
Cell cycle N41329 ATP-binding protein associated with cell differentiation
AA034317 Candidate tumor suppressor protein
H10087 Cyclin A1
BG397188 Cyclin-dependent kinase 5
W94879 HIR histone cell cycle regulation defective homolog A (S. cerevisiae)
R77519 Myeloid cell nuclear differentiation antigen
H15206 NIMA (never in mitosis gene a)-related kinase 3
R13675 p21(CDKN1A)-activated kinase 6
H10435 BRCA1-associated protein
Oncogene BM549678 Cervical cancer 1 protooncogene
BI255100 Cervical cancer 1 protooncogene
W03558 Hepatocellularcarcinoma-associated antigen HCA557a
H49173 Melanoma-associated gene
AA040629 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated
to, 6
H10435 Ovarian carcinoma immunoreactive antigen
H10546 Pim-2 oncogene
AA133961 Pituitary tumor-transforming 1-interacting protein
R55296 Promyelocytic leukemia
H23370 RAB22A, member RAS oncogene family
H02076 T-cell leukemia/lymphoma 1A
R37897 Tumor protein p63
BQ019936 Tumor protein, translationally-controlled 1
W91952 vav 3 oncogene
BF434098 v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)
H29655 v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light
polypeptide gene enhancer in B-cells 3 (avian)
AA005328 v-ski sarcoma viral oncogene homolog (avian)
Transcription factors R66029 Bromodomain adjacent to zinc finger domain, 1A
BM548888 Bromodomain and PHD finger containing, 1
R18948 Cofactor required for Sp1 transcriptional activation, subunit 2, 150kDa
R14275 Cofactor required for Sp1 transcriptional activation, subunit 2, 150kDa
H84735 DNA-directed RNA polymerase II polypeptide J-related gene
AA161069 E1B-55kDa-associated protein 5
T96195 E74-like factor 4 (ets domain transcription factor)
R06038 General transcription factor II, I
R76588 General transcription factor IIIA
AA010526 Glucocorticoid receptor DNA-binding factor 1
BF793857 High-mobility group nucleosome-binding domain 1
H83982 High-mobility group nucleosome-binding domain 1
T80557 High-mobility group protein 2-like 1
R59260 MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C)
BQ003252 MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C)
W69683 Nuclear factor (erythroid-derived 2)-like 1
T77709 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)
N43877 Nuclear receptor subfamily 4, group A, member 3
W35230 Putative DNA/chromatin-binding motif
BE880112 Sp2 transcription factor
H82615 Special AT-rich sequence-binding protein 1 (binds to nuclear matrix/scaffold-associating
DNA’s)
W35313 Sterile -motif and leucine zipper containing kinase AZK
BM904501 TAF12 RNA polymerase II, TATA box-binding protein (TBP)-associated factor, 20 kDa
BE871226 TAF6 RNA polymerase II, TATA box-binding protein (TBP)-associated factor, 80 kDa
R11718 Transcription factor 4
AA029516 Transcription factor 7-like 2 (T-cell specific, HMG-box)
BI907810 Transcription factor B2, mitochondrial
R86677 Zinc finger protein 3 (A8–51)
T99177 Zinc finger protein 317
R12731 Zinc finger protein 335
AA043477 Zinc finger protein 36, C3H type, homolog (mouse)
Category ACCID Genes up-regulated
Apoptosis H45000 Caspase 4, apoptosis-related cysteine protease
R13349 CED-6 protein
Cell cycle AA055894 Anaphase-promoting complex 1 (meiotic checkpoint regulator)
W85770 BUB1 budding uninhibited by benzimidazoles 1 homolog  (yeast)
W40330 G1 to S phase transition 1
R97935 Cell division cycle 34
Oncogene H85307 v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog
R67109 RAB9A, member RAS oncogene family
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that treatment of HeLa cells with garcinol causes the down-
regulation of a larger number of genes (1631 genes) compared
with up-regulation (630 genes). As shown in the inset in Fig.
7, out of 2261 differentially regulated genes, 1445 genes have
been annotated, and 816 genes are either ESTs or are un-
known genes. We sorted out the annotated genes based on the
chromosomal localization and represented this as a bar graph
with differentially regulated genes shown per chromosome
(Fig. 7). It is evident that on most chromosomes the number
of down-regulated genes is higher except on chromosome Y,
where there were no down-regulated genes. When normal-
ized for the total number of genes known per chromosome, it
turns out that 6–8% of the known genes in almost all the
chromosomes were found to be differentially regulated on
treatment with garcinol.
We classified the differentially regulated genes in various
functional categories based on the available annotation in the
public data bases and that supplied by the slide manufacturer.
Some of the interesting categories and the genes that were
either up- or down-regulated are listed in Table II. Among the
up-regulated genes are those for caspase 4 and CED6, which
are pro-apoptotic whereas anti-apoptotic genes like the BCL2
family members and the Fas inhibitory molecule are among the
down-regulated genes. The ubiquitin-conjugating enzyme and
the E3 ubiquitin ligase are up-regulated, which supports the
observed death of treated cells by apoptosis. It was also found
that the genes for the p53-induced protein PIGPC1 and p21
(CDKN1A)-activated kinase 6, which are down-regulated prob-
ably because they are targets of p53 and p21, respectively,
which in turn are regulated by the p300/PCAF histone acetyl-
transferases. Proto-oncogenes form a class of genes of which
more are down-regulated than up-regulated by this treatment,
emphasizing the role of garcinol as a molecule with anti-cancer
activity. Large numbers of differentially regulated genes in-
volved in metabolism and those categorized as transcription
factors or signal transducers have not been included in the
table because of space constraints. The exact significance of the
result is yet to be determined. A large number of unannotated
genes that may have a significant role in cellular functioning
are found to be differentially regulated.
As suggested in a recent review (1), the development of small
molecular weight HAT inhibitors and activators as therapeutic
targets is the next step, following the HDAC inhibitors; some of
which are being tested in clinical trials. Here we show for the
first time that garcinol, a polyisoprenylated benzophenone
from G. indica fruit rind is a small molecule, HAT inhibitor
that can be taken in by cells. There are very few HAT inhibitors
known to date. The first reported HAT inhibitors were bisub-
strate (29) types of inhibitors of p300 and PCAF, which contain
CoA moieties. One of these compounds, Lys-CoA has proven
useful for blocking the HAT activity of p300 specifically.
Though it has been employed for in vitro transcription studies
(12) and in cells via microinjection or with the use of cell-
permeabilizing agents (41), Lys-CoA has generally been inef-
fective with simple addition to cell culture media. The cells
were also found to be not permeable to a PCAF-specific inhib-
itor of the same group, H3-CoA-20, which contains CoA-conju-
gated to a 20-amino acid residue peptide from the N terminus
of histone H3. Recently we have isolated the first naturally
occurring HAT inhibitor, anacardic acid (AA), which inhibits
the HAT activity of both p300 and PCAF very effectively (31).
By using AA as a synthon we have synthesized an amide
derivative of anacardic acid CTPB, which is the only known
small molecule activator of any histone acetyltransferase
(p300). Significantly, CTPB is exclusively specific for p300 HAT
activity. However cells are not permeable or poorly permeable
to both anacardic acid and CTPB.2
We have demonstrated that garcinol not only inhibits the
histone acetylation by p300 and PCAF in vitro (Fig. 2, A and B),
it also represses the acetylation in vivo in HeLa cells (Fig. 2C).
In correlation with this observation and earlier report (42),
garcinol induces apoptosis of HeLa cells in a concentration-de-
pendent manner. Garcinol is known to possess antioxidant and
anticancer chemopreventive activity (Refs. 42 and 43 and ref-
erences therein). Recently it has been shown that garcinol
induces apoptosis in human leukemia cell lines (44). The pres-
ent finding of garcinol as an inhibitor of histone acetyltrans-
ferases may help to further understand the mechanism of gar-
cinol-induced apoptosis.
Presumably, hypoacetylation of histone is a prerequisite of
apoptosis. Though the relationship between acetylation of his-
tones and activation of gene expression is not as direct as it was
believed to be, overall acetylation is a diagnostic feature of
active genes. Thus inhibition of acetylation in vivo would re-
press the majority of the genes. Our microarray analysis of
garcinol-treated HeLa cell gene expression indeed showed that
more than 72% of genes (tested) were down-regulated. (Fig. 7
and Table II). The microarray data further revealed that sev-
eral proto-oncogenes are down-regulated in the presence of
garcinol, suggesting that garcinol may function as an antican-
cer compound. However, a systematic investigation using nor-
mal (untransformed) and different cancerous cell lines are es-
sential to elucidate the specific role of garcinol for cancer
prevention. Because alteration of histone acetylation also has a
causal relation with the manifestation of other diseases,
2 R. A. Varier and T. K. Kundu, unpublished data.
TABLE II—continued
Category ACCIDa Genes down-regulated
Transcription factor T74980 Basic leucine zipper nuclear factor 1 (JEM-1)
H66228 Core-binding factor, runt domain, -subunit 2; translocated to, 3
R39405 Dishevelled, dsh homolog 2 (Drosophila)
AA101861 Heat shock transcription factor 4
R55134 HMG-box transcription factor TCF-3
AA043380 Homeobox D10
R09787 MBD2 (methyl-CpG-binding protein)-interacting zinc finger protein
AA045325 msh homeobox homolog 1 (Drosophila)
R78177 Paired-like homeodomain transcription factor 2
N92222 Putative homeodomain transcription factor 1
R71263 TAF4 RNA polymerase II, TATA box-binding protein (TBP)-associated factor, 135 kDa
R67748 Transcriptional adaptor 2 (ADA2 homolog, yeast)-like
R39430 Transcriptional intermediary factor 1
H14414 Zinc finger protein 195
T80906 Zinc finger protein 28 homolog (mouse)
R23489 Zinc finger protein 354A
a ACCID, GenBankTM accession identification number.
Garcinol, a Naturally Occurring HAT Inhibitor 33725
 by guest, on O
ctober 26, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
namely asthma (45) and AIDS, garcinol or its derivatives may
serve as lead compounds for designing therapeutic targets for
other diseases in addition to cancer.
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